insights_auto
Hvorfor har LYEL gått opp? 6,39%?
Gå mer i dybdenchevron_right
LYEL:NASDAQ
Lyell Immunopharma Inc
7,99 USD
arrow_upward
+6,39%(+0,48) 1 D
14. okt., 16:00:01 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for LYEL …
Åpne
7,42 USD
Høy
8,28 USD
Lav
7,20 USD
Markedsverdi
195,80 mill.
Snittvolum
138,33k
Volum
402,24k
52 u høy
45,00 USD
52 u lav
7,20 USD
EPS
−12,01 USD
Beta
−0,03
Utestående aksjer
24,50 mill.
Antall ansatte
161
Åpne
7,42 USD
Høy
8,28 USD
Lav
7,20 USD
Markedsverdi
195,80 mill.
Snittvolum
138,33k
Volum
402,24k
52 u høy
45,00 USD
52 u lav
7,20 USD
EPS
−12,01 USD
Beta
−0,03
Utestående aksjer
24,50 mill.
Antall ansatte
161
Nyhetssaker
Fra nettkilder og nyhetspartnere
Investing.com Nigeria
·
for 1 døgn siden
Lyell Immunopharma CMO sells $3,641 in shares for tax withholding By Investing.com
Stock Titan
·
for 1 døgn siden
An automatic tax-cover sale leaves Lyell Immunopharma (LYEL) medical chief holding 19,857 shares.
Zacks
·
for 1 døgn siden
Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
Profil
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell, using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors. Wikipedia
Om Lyell Immunopharma Inc
Administrerende direktør-
Ansatte161
Grunnlagt2018
HovedkontorSouth San Francisco, California, USA
Sektor-
Nettstedlyell.com